Table 5.

Literature review

Author (year) [reference number] Institute	Inclusion criteria (n)	EBRT dose (Gy) Median (range)	BT dose (Gy) Median (range)	Local control (%)	Survival	Complication rate (%)
Shiu et al. (1991) [7], Memorial Sloan-Kettering Cancer Centre, USA	Locally advanced/candidate for amputation (33)	–	LDR 44 (25-54)	At 3 yr, 88% At 5 yr, 70%	–	39% (overall)
Harrison et al. (1993) [8], Memorial Sloan-Kettering Cancer Centre, USA	After gross tumor resection BT (intra-operative insertion) vs. no BT, randomized control trial (166)	–	LDR 42-45	At 5 yrs, 82% vs. 67%	5 yr DFS 81% vs. 80%(NS)	14% vs. 10% (NS) (wound complication)
Chaudhary et al. (1998) [9], Tata Memorial Hospital, India	Non-metastatic STS in adults (177)	45 (12-70)	HDR alone 30 (29-50)	At 30 months, 70%, After salvage, 86%	–	< 1%
Rosenblatt et al. (2003) [10], Haifa, Israel	Non-metastatic STS (32)	39.2 (16.2-45)	LDR 33 (18-49), HDR 16	At 3 yrs, 87.5%	At 5 yrs DFS 56%, OS 70%	Wound complication 16%, Late local toxicities 19%
Laskar et al. (2007) [11], Tata Memorial Hospital, India	Non-metastatic STS, children, (median age 13 yrs) (50)	45 (30.6-45)	HDR alone 36 (30-40) EBRT + HDR BT 21 (15-36)	At 51 months, 82%	At 51 months, DFS 68%, OS 71%	Wound complication 4%, Late toxicities 20%
Laskar et al. (2014) [12], Tata Memorial Hospital, India	Non-metastatic STS, children, (Median age 15 yrs) (76)	–	–	At 70 months, 85%	At 70 months, DFS 74%, OS 77%	Wound complication 8%, Late local toxicities 31%
Cortesy et al. (2017) [13], Italy	Primary or recurrent STS (107)	46 (mean)	LDR and PDR 20 (mean?)	At 5 yrs, 80.5%	At 5 yrs, DFS 58.6% OS 87.4%
Current study	Primary STS (27)	50 (30-50)	HDR alone 60.7 (33.4-67.4) EBRT + HDR BT 66.6 (42-78)	At 5 yrs, 85.7%	DFS 39.7 ±3.9 months OS 42.4 ±3.4 months	≥ grade 2 skin toxicity in 14.8% patients

EBRT – external beam radiation therapy; BT – brachytherapy; HDR – high-dose-rate; PDR – pulsed-dose-rate; LDR – low-dose-rate; DFS – disease-free survival; OS – overall survival; yrs – years; NS – not significant